1 most recent filing and news item mentioning EVH. Updated every 60 seconds.
Earnings|GuidanceAug 6, 2026Neutral
Evolent Health reported a 47% increase in Q2 2026 revenue driven by new oncology partnerships, while forecasting 2027 revenue growth of over 25% and adjusted EBITDA margins exceeding $150 million.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.